His primary areas of study are Internal medicine, Surgery, Randomized controlled trial, Hazard ratio and Oncology. His Internal medicine research includes elements of Gastroenterology and Diabetes mellitus, Endocrinology. He has researched Surgery in several fields, including Stroke, Adverse effect and Confidence interval.
His Randomized controlled trial study also includes fields such as
Yasuo Ohashi mostly deals with Internal medicine, Oncology, Surgery, Randomized controlled trial and Breast cancer. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Diabetes mellitus. While the research belongs to areas of Diabetes mellitus, Yasuo Ohashi spends his time largely on the problem of Incidence, intersecting his research to questions surrounding Prospective cohort study.
His Oncology study combines topics from a wide range of disciplines, such as Cancer, Colorectal cancer, Irinotecan, Adjuvant therapy and Quality of life. His studies deal with areas such as Placebo, Adverse effect and Cohort study as well as Surgery. His work deals with themes such as Cyclophosphamide and Docetaxel, which intersect with Breast cancer.
Yasuo Ohashi spends much of his time researching Internal medicine, Oncology, Breast cancer, Randomized controlled trial and Hazard ratio. His Internal medicine study frequently draws connections between related disciplines such as Cardiology. His Oncology research is multidisciplinary, incorporating elements of Quality of life, Cohort and Phases of clinical research.
His Breast cancer study integrates concerns from other disciplines, such as Cyclophosphamide and Adjuvant therapy. The concepts of his Hazard ratio study are interwoven with issues in Diabetes mellitus, Type 2 diabetes, Incidence and Proportional hazards model. His Clinical trial research is multidisciplinary, relying on both Observational study and Prospective cohort study.
His primary areas of investigation include Internal medicine, Oncology, Hazard ratio, Randomized controlled trial and Breast cancer. His study in Diabetes mellitus extends to Internal medicine with its themes. His study in Oncology is interdisciplinary in nature, drawing from both Regimen, Epidermal growth factor receptor, Survival analysis and Phases of clinical research.
His studies examine the connections between Hazard ratio and genetics, as well as such issues in Proportional hazards model, with regards to Nephrology, Kidney disease, Diet therapy, Malnutrition and Mortality rate. Yasuo Ohashi works mostly in the field of Breast cancer, limiting it down to concerns involving Adjuvant therapy and, occasionally, Paclitaxel. His Incidence research integrates issues from Body mass index, Endocrinology, Cohort study and Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and Women: A Meta-analysis
Satoru Kodama;Kazumi Saito;Shiro Tanaka;Miho Maki.
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar;David Preiss;Heather M Murray;Paul Welsh.
The Lancet (2010)
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
Mitsuru Sasako;Shinichi Sakuramoto;Hitoshi Katai;Taira Kinoshita.
Journal of Clinical Oncology (2011)
Primary prevention of cardiovascular disease with pravastatin in Japan (mega study) : A prospective randomised controlled trial
Haruo Nakamura;Kikuo Arakawa;Hiroshige Itakura;Akira Kitabatake.
The Lancet (2006)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im.
The New England Journal of Medicine (2017)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka;Narikazu Boku;Akira Fukutomi;Yukiyasu Okamura.
The Lancet (2016)
EFFECT OF AEROBIC EXERCISE TRAINING ON SERUM LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: A META-ANALYSIS
Satoru Kodama;Shiro Tanaka;Kazumi Saito;Miao Shu.
JAMA Internal Medicine (2007)
Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled Trial
Norio Kohno;Kenjiro Aogi;Hironobu Minami;Seigo Nakamura.
Journal of Clinical Oncology (2005)
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno;Tatsuya Ioka;Masafumi Ikeda;Shinichi Ohkawa.
Journal of Clinical Oncology (2013)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
J. Bergh;K. Pritchard;K. Albain;S. Anderson.
The Lancet (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: